Janney Montgomery Scott
STML

Janney Montgomery Scott’s Stemline Therapeutics, Inc. STML Stock Holding History

Janney Montgomery Scott’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,400
Closed -$108K – 2102
2018
Q4 		$108K Buy
+11,400
New +$148K ﹤0.01% 1860

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Janney Montgomery Scott's STML Position: Q1 2019 in Review

Janney Montgomery Scott sold out of Stemline Therapeutics, Inc. (STML) in Q1 2019, closing a stake of 11,400 shares — an estimated $108K sold.

Janney Montgomery Scott first reported a position in STML in Q4 2018 and held it in 1 quarter. The position peaked at $108K in Q4 2018. 98 funds tracked by Wall St. Rank hold STML as of Q1 2019.

  • Janney Montgomery Scott reported no remaining Stemline Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Janney Montgomery Scott sold 11,400 Stemline Therapeutics, Inc. shares in Q1 2019, an estimated $108K.
  • Janney Montgomery Scott first reported a position in Stemline Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Janney Montgomery Scott's Stemline Therapeutics, Inc. position peaked at $108K in Q4 2018.
  • 98 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2019.

Based on Janney Montgomery Scott's 13F filing for Q1 2019, filed 30 Apr 2019.